Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ANI PharmaceuticalsFRA:BSFA -2.94%78 Operating Margin % is 16.30% as of Mar. 2026, which is 90% above its 10-year median of 8.58. GuruFocus rates FRA:BSFA with a GF Score™ of 78/100 and a GF Value™ of €85.45 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 960 Drug Manufacturers companies, ANI Pharmaceuticals ranks better than 59.69% on this metric.
The historical rank and industry rank for ANI Pharmaceuticals's Operating Margin % or its related term are showing as below:
FRA:BSFA'
s Operating Margin % Range Over the Past 10 Years
Min: -13.03 Med: 8.58 Max: 20.81
Current: 11.46
FRA:BSFA's Operating Margin % is ranked better than 59.69% of 960
companies
in the Drug Manufacturers industry
Industry Median: 7.42
vs FRA:BSFA: 11.46
ANI Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
ANI Pharmaceuticals (FRA:BSFA) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
ANI Pharmaceuticals Operating Margin % Related Terms
ANI Pharmaceuticals Operating Margin % Historical Data
* Premium members only.
The historical data trend for ANI Pharmaceuticals's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BSFA vs TRLV, AMLX, XERS: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANI Pharmaceuticals Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Operating Margin % distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's Operating Margin % falls into.
ANI Pharmaceuticals Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
ANI Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals (FRA:BSFA) has a Operating Margin % of 16.30% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on ANI Pharmaceuticals and its competitors. This is 90% above median its historical median of 8.58. According to the industry distribution chart, ANI Pharmaceuticals ranks #387 out of 960 companies in the Drug Manufacturers industry, placing it in the top 40.3%.
Is ANI Pharmaceuticals' Operating Margin % too high?
ANI Pharmaceuticals' current Operating Margin % of 16.30% is 90% above median its 10-year median of 8.58. The Drug Manufacturers industry median Operating Margin % is 7.42. ANI Pharmaceuticals' value of 16.30% is 119.7% above this industry median. Based on the distribution chart, ANI Pharmaceuticals ranks #387 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ANI Pharmaceuticals has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' Operating Margin % compare to TRLV and AMLX?
According to the Drug Manufacturers industry distribution chart, ANI Pharmaceuticals ranks #387 out of 960 companies for Operating Margin %. This puts ANI Pharmaceuticals in the upper half of its industry. The industry median Operating Margin % is 7.42. ANI Pharmaceuticals' value of 16.30% is 119.7% above this benchmark. While the company's 10-year median is 8.58 vs. the industry median of 7.42, ANI Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.42, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANI Pharmaceuticals's current Operating Margin % of 16.30% is 119.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on ANI Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANI Pharmaceuticals's current Operating Margin % is 16.30%, which is 90% above median its own 10-year median of 8.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (FRA:BSFA) is currently considered Modestly Undervalued. The stock's GF Value™ is €85.45, compared to a current price of €66.00 — trading 22.8% below its estimated fair value. The current Operating Margin % is 16.30%, which is 90% above median its 10-year median of 8.58 and 119.7% above the Drug Manufacturers industry median of 7.42. ANI Pharmaceuticals' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For ANI Pharmaceuticals (FRA:BSFA), the current Operating Margin % is 16.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANI Pharmaceuticals (FRA:BSFA) Overvalued in 2026?
Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued.
The current stock price of €66.00 is trading 22.8% below its estimated GF Value™ of €85.45.
GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for FRA:BSFA:
Operating Margin %: 16.30% (90% above median its 10-year median of 8.58)
GF Value™: €85.45 vs. price of €66.00 (22.8% below fair value)
Industry Position: 119.7% above the Drug Manufacturers median (#387 of 960)
No single metric tells the full story. See the FRA:BSFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
78GF Score
Get the complete analysis for FRA:BSFA
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BSFA has been successfully added to your 
